drugset / Trial / NCT00449319
AML Treatment in Untreated Adult Patients
Unknown
GIMEMA Foundation
Non-randomizedSingle-groupOpen-labelOther
Summary
The present therapy intends to be an homogeneous treatment for AML patients based on a pretreatment with hydroxiurea plus an induction therapy with the standard arm with Daunorubicine as according to EORTC-GIMEMA AML10 study. The post-remissional treatment is based on transplant with HLA compatible donor is foreseen for all patients and autologous transplant for those without HLA compatible donor available.
Timeline
- Start
- 1998-11
- Primary completion
- 2018-06
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daunorubicin | Small molecule | 50 mg/m2 | — |